Impax requested that pharmacists who have dispensed Impax’s epinephrine injection, USP auto-injector 0.3 mg since December 20, 2018 contact all patients who received the device and provide instructions for inspection.
Gabrielle Ientile, Assistant Editor
The study’s authors examined the opportunity to decrease the overall cost of bortezomib by $300-400 million by switching patients to the generic version.
The SIMPLE trial found the 5-day remdesivir treatment arm to be 65% more likely to have clinical improvement compared with standard of care alone in patients with moderate COVID-19.
IW-3718, an investigational adjunct therapy to proton pump inhibitors for refractory GERD, showed favorable results in reducing heartburn severity and other symptoms.
An analysis found that US patients with COVID-19 are experiencing longer hospital stays and higher rates of ICU admissions than patients in China.
FDA OKs Ticagrelor Indication to Reduce Risk of First Heart Attack, Stroke in Patients With High-Risk CAD
This is the first regulatory approval for aspirin plus ticagrelor dual antiplatelet therapy for individuals with high cardiovascular risk but without prior instances of heart attack or stroke.
ASCO20 Virtual: Pembrolizumab Doubles Progression-Free Survival for Certain Advanced Colorectal Cancer Types
The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.
“Data collection is ongoing with additional analyses planned to look at patient and provider perception of COVID-19 impact on cancer care.”
SOLO-2 is the first phase 3 trial to provide overall survival (OS) data on maintenance PARP inhibitor therapy.
The study is the first of its kind on a national scale to show the benefit of Medicaid expansion on cancer mortality rates.